

Figure S1

217 unresectable hepatocellular carcinoma patients treated with PD-1 inhibitor plus antiangiogenic agent from April 26<sup>th</sup>, 2018 to July 24<sup>th</sup>, 2021

Exclude: n=81

- Accepted combined therapy for less than two cycles (n=28)
- No available follow-up data (n=16)
- No data for baseline assessment and response assessment (n=26)
- Diagnosed of a second primary tumor in recently 5 years (n=4)
- Pathologic finding was hepatocellular carcinoma with sarcoma or hepatic neuroendocrine carcinoma (n=7)

136 patients were eligible for assessment

15 patients not evaluable for best response

9 patients had no data of survival analysis

Best response and time-to-progression (TTP) assessment (n=121)

Progression-free survival (PFS) and safety assessment (n=136)

overall survival (OS) assessment (n=127)

Figure S2

